|
AR038136A1
(es)
*
|
2002-01-24 |
2004-12-29 |
Merck Frosst Canada Inc |
Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
|
|
AR041089A1
(es)
*
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
|
PL1833791T3
(pl)
|
2004-12-27 |
2011-12-30 |
Actelion Pharmaceuticals Ltd |
Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
|
|
US20080139604A1
(en)
*
|
2005-02-17 |
2008-06-12 |
Shaun Fitzpatrick |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
|
WO2007002181A2
(en)
|
2005-06-24 |
2007-01-04 |
Eli Lilly And Company |
Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
|
|
EP1916245B1
(en)
|
2005-07-22 |
2011-10-26 |
Shionogi & Co., Ltd. |
Indole derivative having pgd2 receptor antagonist activity
|
|
WO2007010965A1
(ja)
|
2005-07-22 |
2007-01-25 |
Shionogi & Co., Ltd. |
Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
|
|
JP5147401B2
(ja)
|
2005-09-06 |
2013-02-20 |
塩野義製薬株式会社 |
Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
|
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
|
KR101411820B1
(ko)
|
2006-08-07 |
2014-06-24 |
액테리온 파마슈티칼 리미티드 |
(3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
|
|
WO2008039882A1
(en)
*
|
2006-09-30 |
2008-04-03 |
Sanofi-Aventis U.S. Llc |
A combination of niacin and a prostaglandin d2 receptor antagonist
|
|
UA98777C2
(en)
|
2006-11-20 |
2012-06-25 |
Эли Лилли Энд Компани |
Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
|
|
EP2114154B1
(en)
*
|
2007-02-08 |
2013-08-28 |
Merck Sharp & Dohme Corp. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
|
AR065670A1
(es)
|
2007-03-09 |
2009-06-24 |
Indigene Pharmaceuticals Inc |
Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
|
|
BRPI0907364A2
(pt)
|
2008-02-01 |
2015-07-14 |
Amira Pharmaceuticals Inc |
Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
|
|
UA98839C2
(en)
*
|
2008-02-01 |
2012-06-25 |
Панмира Фармасьютикалз, Ллк. |
N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
|
|
WO2009102893A2
(en)
*
|
2008-02-14 |
2009-08-20 |
Amira Pharmaceuticals, Inc. |
CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
|
|
WO2009108720A2
(en)
*
|
2008-02-25 |
2009-09-03 |
Amira Pharmaceuticals, Inc. |
Antagonists of prostaglandin d2 receptors
|
|
WO2009145989A2
(en)
*
|
2008-04-02 |
2009-12-03 |
Amira Pharmaceuticals, Inc. |
Aminoalkylphenyl antagonists of prostaglandin d2 receptors
|
|
EP2119705A1
(en)
*
|
2008-05-14 |
2009-11-18 |
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. |
3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
|
|
CN102026974B
(zh)
|
2008-05-16 |
2013-08-28 |
伊莱利利公司 |
四氢环戊二烯并[b]吲哚雄激素受体调节剂
|
|
BRPI0912842A8
(pt)
*
|
2008-05-20 |
2019-01-29 |
Cerenis Therapeutics Holding |
composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
|
|
AU2009266793B2
(en)
*
|
2008-07-03 |
2012-12-20 |
Brickell Biotech, Inc. |
Antagonists of prostaglandin D2 receptors
|
|
GB2463788B
(en)
*
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
WO2010042652A2
(en)
|
2008-10-08 |
2010-04-15 |
Amira Pharmaceuticals, Inc. |
Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
|
|
WO2010057118A2
(en)
*
|
2008-11-17 |
2010-05-20 |
Amira Pharmaceuticals, Inc. |
Heterocyclic antagonists of prostaglandin d2 receptors
|
|
US20100173313A1
(en)
*
|
2009-01-08 |
2010-07-08 |
Amira Pharmaceuticals, Inc. |
Biomarkers of inflammation
|
|
EP2461809A4
(en)
|
2009-07-31 |
2013-06-19 |
Panmira Pharmaceuticals Llc |
OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
|
|
EP2462110A4
(en)
*
|
2009-08-05 |
2013-04-03 |
Panmira Pharmaceuticals Llc |
DP2 ANTAGONIST AND USES THEREOF
|
|
AU2011203649A1
(en)
|
2010-01-06 |
2012-06-14 |
Brickell Biotech, Inc. |
DP2 antagonist and uses thereof
|
|
WO2011117798A1
(en)
*
|
2010-03-22 |
2011-09-29 |
Actelion Pharmaceuticals Ltd |
3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
|
|
MY165623A
(en)
|
2011-04-14 |
2018-04-18 |
Idorsia Pharmaceuticals Ltd |
7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
|
|
HRP20181555T1
(hr)
|
2014-03-17 |
2018-11-30 |
Idorsia Pharmaceuticals Ltd |
Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2
|
|
RU2016140708A
(ru)
|
2014-03-18 |
2018-04-18 |
Идорсиа Фармасьютиклз Лтд |
Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
|
|
CN106032383B
(zh)
*
|
2015-03-19 |
2019-08-13 |
中国科学院上海药物研究所 |
一类三环类似物、其制备方法和用途
|
|
PL3350179T3
(pl)
|
2015-09-15 |
2021-08-02 |
Idorsia Pharmaceuticals Ltd |
Krystaliczne postacie
|
|
CN112362781A
(zh)
*
|
2020-11-09 |
2021-02-12 |
河北诚信集团有限公司 |
一种甲基亚磺酸钠的含量测定方法
|